CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

After landmark deal, AstraZeneca goes to CSPC again in up to $1.7B pact

PartnershipPositive
AI Analysis

Summary

AstraZeneca has entered into a second drug R&D collaboration with Chinese partner CSPC worth up to $1.7B, less than six months after a landmark deal between the two companies.

Importance:7/10
Sentiment:
0.60
partnershipcollaborationChinadrug developmentlicensing
Related Companies

Read the original article

Published by Endpoints News on July 2, 2026 5:06 PM

Read Original